Chiwoo Oh: AS01B Adjuvant and Long-Term Immune Reprogramming After Shingrix Vaccination
Chiwoo Oh, Postdoctoral Research Fellow at Harvard Medical School, shared a post on LinkedIn about recent article by Fabiana Corsi-Zuelli et al, published in Nature Medicine, adding:
“The AS01B adjuvant (MPL plus QS 21) in Shingrix initially induces strong innate immune activation but subsequently causes long term reprogramming of the chromatin and transcriptional state of monocytes, reducing inflammatory cytokine responses such as IL6 upon subsequent TLR stimulation.
This may, in turn, decrease chronic vascular and atherosclerosis-associated inflammation, potentially lowering the risk of cardiovascular events.”
Title: Recombinant shingles vaccination and the risk of cardiovascular events
Authors: Fabiana Corsi-Zuelli, Fang Li, Rachel Upthegrove, John A. Todd, Betty Raman, Paul J. Harrison, Maxime Taquet
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 3, 2026, 20:33Jennifer Weinstein: Happy to Share Our New Work on the Patient Experience in VWD at the NBDF Conference
-
Sep 3, 2026, 20:31Guillaume Courbon: New Publication on Erythroid-Produced FGF23 and Its Role in Anemia
-
Sep 3, 2026, 20:30Phuong Khanh Morrow: FDA Approval Marks an Important Step Forward for the PV Community
-
Sep 3, 2026, 20:29Sarah Robins: Happy to Share This Portrait Film I Voiced for the NNHHF
-
Sep 3, 2026, 20:27Mireille Muller: Europe Needs More Plasma Donors
-
Sep 3, 2026, 17:54Tareq Abadl: Extravascular Hemolysis The High-Yield Guide
-
Sep 3, 2026, 17:48Isabel Sá: Starting a New Chapter as a Clinical Scientist in Molecular Genetics and Haematology
-
Sep 3, 2026, 17:35Key Developments in Transfusion Medicine and Biotherapies in 2025 – AABB
-
Sep 3, 2026, 17:24N. Mariana S. Vasquez: JAK2 Mutations The High-Yield Map of Myeloproliferative Neoplasms